Related Experiment Video

Updated: Jul 26, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Rate of palivizumab administration in accordance with current recommendations among hospitalized children

James A Moynihan1, Tommy Y Kim, Tammy Young

  • 1Department of Emergency Medicine at Loma Linda University Medical Center & Children's Hospital, Department of Pediatric Emergency Medicine, Loma Linda, Calif, USA.

Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners
|September 1, 2004
PubMed

Insights

Palivizumab prophylaxis is recommended for high-risk infants to prevent severe respiratory syncytial virus (RSV) infection. However, only 35% of eligible hospitalized children received this important preventative treatment, indicating barriers to its administration.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Public Health

Background:

  • The American Academy of Pediatrics recommends palivizumab prophylaxis for premature infants and those with chronic lung disease to mitigate respiratory syncytial virus (RSV) infection severity.
  • RSV infection poses a significant health risk to vulnerable pediatric populations, necessitating effective preventative strategies.

Purpose of the Study:

  • To investigate the administration patterns of palivizumab among children hospitalized with RSV infection.
  • To identify potential barriers affecting the uptake of palivizumab prophylaxis in a pediatric hospital setting.

Main Methods:

  • A retrospective medical record review was conducted at a tertiary care children's hospital.
  • The study included children under 2 years of age hospitalized with RSV infection between October 1, 2000, and April 1, 2001.

Main Results:

  • Records of 264 children with RSV infection were analyzed.
  • Forty children met the criteria for palivizumab administration based on AAP guidelines.
  • Only 14 (35%) of eligible children received palivizumab prior to hospital admission.
  • Palivizumab administration rates were not influenced by patient age, race, or insurance status.

Conclusions:

  • The precise obstacles to palivizumab administration require further elucidation.
  • Identifying at-risk children and improving collaboration between healthcare providers are crucial for increasing palivizumab use and reducing RSV incidence.
  • Effective implementation of palivizumab prophylaxis can decrease the burden of RSV infections in high-risk pediatric populations.
Abstract

More Related Videos

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...